These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36618180)

  • 21. Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study.
    Kamal D; Thakur V; Nath N; Malhotra T; Gupta A; Batlish R
    Med J Armed Forces India; 2021 Jul; 77(Suppl 2):S283-S288. PubMed ID: 34334895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of safety and adverse drug reactions of COVID vaccination in the South Indian population: An observational prospective cross-sectional study.
    Manda A; Koya P; Pallem R; Mohd D; Thatikonda K; Venkateshwarlu K
    Ann Med Surg (Lond); 2022 Dec; 84():104948. PubMed ID: 36536701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of associated events following AZD1222 (Covishield) vaccination in a high-risk population in Nepal.
    Poudel KM; Shah N; Prakash M; Deo SK; Bhandari S; Poudel TR
    BMC Infect Dis; 2022 May; 22(1):422. PubMed ID: 35505278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021.
    Tran VN; Nguyen HA; Le TTA; Truong TT; Nguyen PT; Nguyen TTH
    Vaccine; 2021 Oct; 39(44):6485-6491. PubMed ID: 34607748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How safe is COVID-19 vaccination among pregnant women and its outcome - A hospital-based retrospective study in Indian population.
    Pandit NB; Fulmali PR; Chandrayan P; Chauhan K; Bhil DL; Rasania MN
    J Family Med Prim Care; 2023 Sep; 12(9):2140-2145. PubMed ID: 38024942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis.
    Contractor A; Shivaprakash S; Tiwari A; Setia MS; Gianchandani T
    PLoS One; 2022; 17(10):e0276759. PubMed ID: 36301977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia.
    Supangat ; Sakinah EN; Nugraha MY; Qodar TS; Mulyono BW; Tohari AI
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):58. PubMed ID: 34641944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acceptance and Attitude of Parents Regarding COVID-19 Vaccine for Children: A Cross-Sectional Study.
    Mohan R; Pandey V; Kumar A; Gangadevi P; Goel AD; Joseph J; Kurien N
    Cureus; 2022 Apr; 14(4):e24518. PubMed ID: 35651474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Comparative Study of Deaths Due to the COVID-19 Pandemic During the First and Second Waves in a Tertiary Care Center of a Rural Area in South India.
    Navab R; R A; M A U; P E D; Kamatchi S; Yeragudi Jangamareddy VR
    Cureus; 2024 Jan; 16(1):e52184. PubMed ID: 38348000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse Events among Beneficiaries who Received a Dose of Sputnik V Vaccine at a Tertiary Care Hospital in Coastal Karnataka, India.
    Ameer BR; Akshaya KM; Bhargava M; Jamal J
    Indian J Community Med; 2023; 48(3):418-421. PubMed ID: 37469916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Analysis of Antibody Response to COVID-19 Vaccination Among Medicos in a Predominantly Tribal State in India: A Comparative Study.
    Kiran KA; Kumari S; Saroj U; Kujur M; Kujur A; Kumar M; Narain S; N V; K J
    Cureus; 2024 May; 16(5):e61154. PubMed ID: 38933647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19 vaccination: Is it a matter of concern?
    Kushwaha P; Pundhir A; Gahlot A
    J Family Med Prim Care; 2022 Jun; 11(6):2431-2436. PubMed ID: 36119229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. To Study Adverse Effect following Immunization (AEFI) and COVID-19 Infection amongst COVID-19 Vaccine Benefeciaries.
    N PP; S CS; F JV; B AB; A KM; T DP; N GC; R IA
    J Assoc Physicians India; 2022 Feb; 70(2):11-12. PubMed ID: 35436817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse events and breakthrough infections associated with COVID-19 vaccination in the Indian population.
    Arora G; Taneja J; Bhardwaj P; Goyal S; Naidu K; Yadav SK; Saluja D; Jetly S
    J Med Virol; 2022 Jul; 94(7):3147-3154. PubMed ID: 35261064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute Adverse Effects of Vaccines Against SARS-COV-2.
    Mahmood A; Shujaat SA; Hayat M; Ijaz F; Habib S; Sadaqat W; Aftab RK; Inam SHA
    Cureus; 2022 Jul; 14(7):e27379. PubMed ID: 36046318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse events following the first dose of Covishield (ChAdOx1 nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study.
    Subedi P; Yadav GK; Paudel B; Regmi A; Pyakurel P
    PLoS One; 2021; 16(12):e0260638. PubMed ID: 34932553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variations and Associated Factors in Symptom-to-Balloon (STB) Time and Door-to-Balloon (DTB) Time Before and After the COVID-19 Lockdown: A Hospital-Based Cross-Sectional Study.
    Mohandas NV; K V; Sreedevi A; George N; Eapen K; Subramanian S; Raj H; Menon JC
    Cureus; 2023 Oct; 15(10):e47658. PubMed ID: 38022374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A cross sectional study exploring determinants for vaccine awareness, belief and hesitancy among health care professionals regarding Covid-19 vaccine, findings from a teaching hospital based in coal capital of India.
    Thakur S; Rana RK; Kumari M; Jha RR; Bhushan R; Verma RK
    J Family Med Prim Care; 2021 Dec; 10(12):4578-4585. PubMed ID: 35280613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Prospective Observational Study on BBV152 Coronavirus Vaccine Use in Adolescents and Comparison with Adults: Interim Results of the First Real-World Safety Analysis.
    Kaur U; K L A; Chauhan M; Joshi A; Das A; Kansal S; Jaisawal V; Patwardhan K; Chakrabarti SS
    Drug Saf; 2022 Oct; 45(10):1099-1109. PubMed ID: 36030299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.